目的：探讨不同途径输注DC-CIK对中晚期原发性肝癌（PLC）的治疗效果和预后价值。方法：回顾性分析2018年 10月至2021年9月间东部战区总医院肿瘤科DC-CIK治疗的69例中晚期PLC患者的临床资料，根据DC-CIK治疗时采用的输注 方式不同将患者分为肝动脉灌注（HAI）组（n = 29）和静脉输注（IV）组（n = 40），比较两组患者的临床疗效、外周血T淋巴细胞亚 群（CD3+ 、CD4 + 、CD8 + T和CD4+ /CD8+ T细胞比值），以及细胞因子（IL-2、IL-6、IFN-γ和TNF-α）、甲胎蛋白（AFP）的变化、总生存期 （OS）和不良反应发生情况。结果：69例PLC患者经DC-CIK治疗后，HAI组患者的客观缓解率（ORR）为0%，疾病控制率（DCR） 为75.8%；IV组患者的ORR为0%，DCR为72.5%（P > 0.05）。两组患者治疗前后T淋巴细胞亚群指标变化差异无统计学意义（均 P > 0.05），两组患者治疗后外周血IL-2、IL-6、IFN-γ和TNF-α的平均水平均显著高于治疗前（均P < 0.01），两组间比较无显著差异 （P > 0.05）；HAI组患者平均OS为48.17个月，IV组OS为39.65个月，两组间比较无显著差异（P > 0.05）。治疗过程中无严重不良 反应发生。结论：自体DC-CIK HAI治疗PLC安全有效，较IV治疗有提升临床获益的趋势，值得临床借鉴。

Objective: To explore the therapeutic effects and prognostic value of dendritic cell and cytokine-induced killer cell (DC-CIK) infusion in different routes in the treatment of intermediate and advanced primary liver cancer (PLC). Methods: A retrospective study was conducted on the clinical data of 69 patients with intermediate and advanced PLC treated with DC-CIK at the Oncology Department of the General Hospital of the Eastern Theater of Operations between October 2018 and September 2021. The patients were divided into a hepatic arterial infusion (HAI) group (n = 29) and an intravenous infusion (IV) group (n = 40) according to the different infusion modes used for DC-CIK treatment. The changes in peripheral blood T lymphocyte subsets (CD3+ , CD4+ , CD8+ T cells and CD4+ /CD8+ T cell ratio), cytokines (IL-2, IL-6, IFN-γ, and TNF-α), and alpha-fetoprotein (AFP) before and after treatment, treatment efficacy, overall survival (OS), and the incidence of adverse reactions were compared between the two groups. Results: After DC-CIK treatment, the objective remission rate (ORR) was 0%, and the disease control rate (DCR) was 75.8% in the HAI group; the ORR was 0%, and the DCR was 72.5% in the IV group (all P > 0.05). There were no significant changes in T-lymphocyte subpopulation between the two groups before and after treatment (all P > 0.05). The mean levels of peripheral blood IL-2, IL-6, IFN- γ and TNF- α after treatment were significantly higher than those before treatment in both groups (all P < 0.01), but with no significant difference between the two groups (all P > 0.05). The mean OS in HAI group was 48.17 months, and the OS in IV group was 39.65 months, with no significant difference between the two groups (P > 0.05). No severe adverse reactions occurred during the treatment. Conclusion: Autologous DC-CIK treatment via HAI is safe and effective for PLC. Compared to IV treatment, it tends to further improve the clinical benefit, which is worthy of clinical reference.

东部战区总医院院管课题（No. 22JCYYYB1）